Advertisement

Hyperprolaktinämie

  • Frank Nawroth
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Prolaktin bereitet häufig Probleme bei der Interpretation und ist daher ein möglicher Ausgangspunkt fragwürdiger diagnostischer und therapeutischer Entscheidungen. Unsicherheit besteht oft hinsichtlich der Notwendigkeit einer bildgebenden Diagnostik, dem Follow-up auffälliger Werte, dem Verhalten bei Zyklusstörungen, bei Kinderwunsch, in der Schwangerschaft und Stillzeit. Das Kapitel beschäftigt sich mit den genannten Punkten, fasst das praxisrelevante Wissen zusammen und erarbeitet mögliche Flussschemata für das tägliche Handeln in der Routine.

Literatur

  1. Arden KC, Boutin JM, Djiane J, Kelly PA, Cavenee WK (1990) The receptors for prolactin and growth hormone are localized in the same region of human chromosome 5. Cytogenet Cell Genet 53:161–165CrossRefPubMedGoogle Scholar
  2. Astwood EB (1941) The regulation of corpus luteum function by hypophysial luteotrophin. Endocrinology 29:309–319CrossRefGoogle Scholar
  3. Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A (2013a) Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 169:359–366CrossRefPubMedGoogle Scholar
  4. Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A (2013b) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98:372–379CrossRefPubMedGoogle Scholar
  5. Barlier A, Jaquet P (2006) Quinagolide – a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 154:187–195CrossRefPubMedGoogle Scholar
  6. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation and clinical aspects. Endocr Rev 17:639–669PubMedGoogle Scholar
  7. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268CrossRefPubMedGoogle Scholar
  8. Clemens JA, Roush ME, Fuller RW (1978) Evidence that serotonin neurons stimulate secretion of prolactin releasing factor. Life Sci 22:2209–2213CrossRefPubMedGoogle Scholar
  9. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033CrossRefPubMedGoogle Scholar
  10. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43–51CrossRefPubMedGoogle Scholar
  11. Goffin V, Shiverick KT, Kelly PA, Martial JA (1996) Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 17:385–410PubMedGoogle Scholar
  12. Goffin V, Binart N, Touraine P, Kelly PA (2002) Prolactin. The new biology of an old hormone. Annu Rev Physiol 64:47–67CrossRefPubMedGoogle Scholar
  13. Golander A, Hurley T, Barret J, Hizi A, Handwerger S (1978) Prolactin synthesis by human chorion-decidual tissue: a possible source of prolactin in the amniotic fluid. Science 202:311–313CrossRefPubMedGoogle Scholar
  14. Jacobs LS, Snyder PJ, Wilbur JF, Utiger RD, Daughaday WH (1971) Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab 33:996–998CrossRefPubMedGoogle Scholar
  15. Maslar IA, Riddick DH (1979) Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 135:751–754CrossRefPubMedGoogle Scholar
  16. McNatty KP, Sawers RS, McNeilly AS (1974) A possible role for prolactin in control of steroid secretion by the Graafian follicle. Nature 250:653–655CrossRefPubMedGoogle Scholar
  17. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMedGoogle Scholar
  18. Molitch ME, Russell EJ (1990) The pituitary „incidentaloma“. Ann Intern Med 112:925–931CrossRefPubMedGoogle Scholar
  19. Naliato EC, Violante AH, Caldas D, Farias ML, Bussade I, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Loures T, Colao A (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11:21–28CrossRefPubMedGoogle Scholar
  20. Nawroth F (2005) Hyperprolactinemia and the regular menstrual cycle in asymptomatic women – should it be treated during therapy of infertility? Reprod Biomed Online 11:581–588CrossRefPubMedGoogle Scholar
  21. Nawroth F, Ludwig M (2007) Persistierende Hyperprolaktinämie ohne Zyklusstörungen. Frauenarzt 48:454–459Google Scholar
  22. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679CrossRefPubMedGoogle Scholar
  23. Phelps JY, Bugg EM, Shamblott MJ, Vlahos NP, Whelan J, Zacur HA (2003) Prolactin gene expression in human ovarian follicular cells. Fertil Steril 79:182–185CrossRefPubMedGoogle Scholar
  24. Posner BI, Kelly PA, Shiu RP, Friesen HG (1974) Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation and characterization. Endocrinology 95:521–531CrossRefPubMedGoogle Scholar
  25. Raber W, Gessl A, Nowotny P, Vierhapper H (2003) Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization. Clin Endocrinol 58:185–191CrossRefGoogle Scholar
  26. Riddle O, Bates RW, Dykshorn SW (1933) The preparation, identification and assay of prolactin – a hormone of the anterior pituitary. Am J Phys 105:191–216Google Scholar
  27. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38CrossRefPubMedGoogle Scholar
  28. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418CrossRefPubMedGoogle Scholar
  29. Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354–396CrossRefPubMedGoogle Scholar
  30. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, Martin NM (2010) Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol 73:369–374CrossRefGoogle Scholar
  31. Vartej P, Poiana C, Vartej I (2001) Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 15:43–47CrossRefPubMedGoogle Scholar
  32. Velasquez EV, Trigo RV, Creus S, Campo S, Croxatto HB (2006a) Pituitary-ovarian axis during lactational amenorrhoea. I. Longitudinal assessment of follicular growth, gonadotrophins, sex steroids and inhibin levels before and after recovery of menstrual cyclicity. Hum Reprod 21:909–915CrossRefPubMedGoogle Scholar
  33. Velasquez EV, Creus S, Trigo RV, Cigorraga SB, Pellizzari EH, Croxatto HB, Campo S (2006b) Pituitary-ovarian axis during lactational amenorrhoea. II. Longitudinal assessment of serum FSH polymorphism before and after recovery of menstrual cycles. Hum Reprod 21:916–923CrossRefPubMedGoogle Scholar
  34. Verhelst J, Abs R (2003) Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2:23–32CrossRefPubMedGoogle Scholar
  35. Yazigi RA, Quintero CH, Salameh WA (1997) Prolactin disorders. Fertil Steril 67:215–225CrossRefPubMedGoogle Scholar
  36. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Facharzt-Zentrum für Kinderwunsch, Pränatale Medizin, Endokrinologie und Osteologieamedes MVZ HamburgHamburgDeutschland

Personalised recommendations